Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Biohaven Ltd. (NYSE:BHVN) have received a consensus rating of “Moderate Buy” from the eighteen brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $21.6250.

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Biohaven in a research report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Leerink Partners reissued an “outperform” rating and issued a $15.00 price target on shares of Biohaven in a report on Tuesday, March 3rd. HC Wainwright reiterated a “neutral” rating and issued a $10.00 price objective on shares of Biohaven in a research report on Tuesday, May 26th. Finally, Royal Bank Of Canada decreased their target price on Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th.

Hedge Funds Weigh In On Biohaven

A number of large investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its position in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the last quarter. Suvretta Capital Management LLC lifted its stake in Biohaven by 83.0% in the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after purchasing an additional 4,666,666 shares during the last quarter. Stifel Financial Corp lifted its holdings in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after purchasing an additional 3,328,506 shares during the last quarter. Infinitum Asset Management LLC lifted its position in Biohaven by 267.6% during the fourth quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after acquiring an additional 4,550,000 shares during the last quarter. Finally, State Street Corp lifted its position in Biohaven by 34.2% during the fourth quarter. State Street Corp now owns 5,716,487 shares of the company’s stock worth $64,539,000 after acquiring an additional 1,458,204 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Stock Down 5.3%

BHVN stock opened at $14.99 on Tuesday. The company has a fifty day simple moving average of $10.99 and a 200 day simple moving average of $10.86. Biohaven has a 1 year low of $7.48 and a 1 year high of $18.57. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The firm has a market cap of $2.26 billion, a PE ratio of -2.64 and a beta of 1.35.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Sell-side analysts anticipate that Biohaven will post -3.1 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.